#8,650 by institutional money · Stock
Neuphoria Therapeutics Inc. (NEUP)
Institutional ownership from Q3 2026 Form 13F filings
$2.32
+1.75% today
Market closed. Prices as of Nov 20, 3:41 AM ET
- 13F holders
- 19 (−3)
- Held by 13F filers, live
- $4.1M
- Shares held
- 1,766,421
- Share of stock outstanding
- 32.6%
- Net buying in Q3 2026
- −$528K
- New positions / sold out
- 5 / 8
Largest holders
19 investors| Investor | Shares | Value, live | % of their portfolio | vs Q2 2026 |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 875,328 | $2.0M | 0.35% | Unchanged |
| AdvisorShares Investments LLC | 312,895 | $726K | 0.10% | Added +24% |
| Vanguard Capital Management LLC | 173,488 | $402K | <0.1% | Unchanged |
| Shay Capital LLC | 130,021 | $302K | <0.1% | Reduced −17% |
| Geode Capital Management, LLC | 50,636 | $117K | <0.1% | Added +2% |
| Ikarian Capital, LLC | 47,443 | $110K | <0.1% | Unchanged |
| Citadel Advisors LLC Ken Griffin | 44,045 | $102K | <0.1% | Reduced −39% |
| Vanguard Fiduciary Trust Co | 33,806 | $78K | <0.1% | Unchanged |
| ADAR1 Capital Management, LLC | 30,000 | $70K | <0.1% | Unchanged |
| Jane Street Group, LLC | 18,171 | $42K | <0.1% | Added +22% |
| Susquehanna International Group, LLP | 14,732 | $34K | <0.1% | New |
| Boothbay Fund Management, LLC | 14,000 | $32K | <0.1% | Unchanged |
| GTS Securities LLC | 11,487 | $27K | <0.1% | New |
| Merck & Co., Inc. | 10,027 | $23K | <0.1% | Unchanged |
| UBS Group AG | 224 | $520 | <0.1% | Reduced −89% |
| Morgan Stanley | 58 | $135 | <0.1% | Unchanged |
| Allworth Financial LP | 41 | $95 | <0.1% | New |
| FMR LLC | 16 | $37 | <0.1% | New |
| Barclays Plc | 3 | $7 | <0.1% | New |